12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Uceris budesonide MMX regulatory update

FDA approved an NDA from Santarus for Uceris budesonide to induce remission of mild to moderate active ulcerative colitis (UC). Santarus said it plans to launch Uceris in the U.S. in March. The company said it has...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >